TB-CHAMP Trial Reveals key risk factors for TB Infection in children under five years of age.Young children have a high risk ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

Infectious Diseases, Department of Internal Medicine, Nanavati Max Super Speciality Hospital, highlights the effectiveness of ...

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

Iterum Therapeutics Announces Partnership for Commercialization Services U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at ...

FDA recommends inclusion of patients as young as 6 months - younger than Moleculin had proposed - to be allowed in the ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

A new review has examined how bipolar disorder medications interact with the gut microbiome, revealing important links ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months - younger than ...

Treating urine infections is becoming increasingly challenging due to rising antibiotic resistance. Here's what's driving this issue and how to address it.

By enabling early risk stratification ... Keywords: machine learning models, neurosurgical postoperative care, multidrug-resistant bacterial pneumonia, Influencing factors, SHAP interpretability ...